AboGen is a commercial-stage medical device company that has developed transformative technology: a saliva collection and preservation technology designed to preserve all the components in saliva and potentially replace up to 80% of the 5 billion blood tests performed annually.
Only two million oral fluid collection kits are sold yearly in the U.S. as they are appropriate solely for genetic testing; they do not allow for isolating blood cells or other extracellular proteins and factors. AboGen’s kit allows users to capitalize on the robustness of saliva by rendering all its diverse components preservable and accessible for diagnostic testing.
There are five (5) billion tests performed annually in the U.S. using blood. While saliva is a more user-friendly sampling technology, its use has been strictly limited to just a few applications because of numerous challenges. Now, AboGen has developed a saliva collection & preservation device that has overcome these hurdles, and can process 80% of the same components as blood.
“I wanted to conduct molecular studies on a family with early onset Alzheimer’s disease. My studies required sample collection from patients living in remote areas; therefore, blood was not a suitable sampling material. AboGen’s saliva collection & preservation kit greatly enabled my research,” says Fereshteh Jahaniani, Ph.D, Stanford Center for Genomics and Personalized Medicine.
Two of the most notable potential applications for the AboGen saliva collection & preservation are for HIV rapid detection and COPD monitoring. Given that the AboGen kit can be used at home to collect saliva, T-cell monitoring of HIV-infected patients to check drug efficacy is readily facilitated, while monitoring of COPD patients is a critical success factor in managing this disease.
AboGen CEO and Co-Founder Stephen Andrews is an adjunct professor at University of New England. He earned a bachelor’s degree in Microbiology and Immunology and a PhD in Pharmacology and Therapeutics at McGill University, which ranks first in Canada among medical-doctoral universities. Dr. Andrews was a postdoctoral researcher at the esteemed UNC Carolina Population Center.
AboGen President and Co-Founder Youssef Biadillah is a biomedical engineer with a grand knack for commercializing technology. Author of 50+ patents and applications, he was a member of the core team at Sadra Medical (Boston Scientific) that developed Lotus™ Valve System, the world’s first fully repositionable and retrievable prosthesis for TAVR. He founded Koios Medical Technologies, which has spun-out Anchor Orthopedics XT and AboGen. And, he has helped Symetis and Xeltis refine their transformative technologies.